About the 15th Annual Biotech in Europe Forum

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600+ delegates and 100+ presenting companies.

The 15th Annual is held for the second time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

The Meeting will provide a number of networking opportunities via our online 1-2-1 meeting system which allows you to pre-book meetings with all the attendees. We expect more than 1500 meetings to take place throughout the 2 days. 

Additionally there will be social events on the evenings of the conference, with a reception at The Grand Hotel Les Trois Rois hosted by The Canton of Basel-Stadt on 29th of September.

Forum Panels included:

  • Public Markets and M&A 
  • Raising Capital Outside Europe
  • Early and Late Stage Investment [2 sessions]
  • Early and Late Stage Licensing [2 sessions]
  • Cell and Gene Therapies: Recent Advances
  • Academic Collaborations & Tech Transfer
  • Personalised Medicine & Diagnostics
 
Therapeutic Panels:
Autoimmune & Inflammatory
CV & Metabolic Diseases/Diabetes
Infectious Diseases
CNS & Pain [2 sessions]
Oncology [3 sessions]
Orphan and Rare Diseases
Platform Technologies & Novel Therapeutics
Vaccines


​Speakers & Chairs included:

Keynote Speakers:
  • Jason Coloma, Head of Oncology and Cancer Immunology Partnering, Roche
  • Susan Herbert, Executive Vice-President, Global Business Development and Strategy, Merck Serono
  • Vivek Ramaswamy, CEO, Axovant Sciences

Speakers & Chairs:
  • Adam Kostyál, Senior Vice President GCCG, Nasdaq Stockholm AB
  • Alain Huriez, Partner, Advent Life Sciences
  • Anish Bhatnagar, President and CEO, CAPNIA, Inc.
  • Anne Portwich, Partner, Life Science Partners
  • Antonius Schuh, CEO, Trovagene, Inc.
  • Arthur Franken, Partner, Gilde Healthcare Partners
  • Austin Smith, Medical Director, Theradex Europe Ltd.
  • B. Chandler May, President & Chief Executive Officer, Inflammatory Response Research, Inc.
  • Barbara Domayne-Hayman, CBO, Autifony Therapeutics Ltd.
  • Barry Ticho MD, Head, Cardiovascular and Metabolic Disorders, External R&D Innovation (ERDI), Worldwide Research & Development, Pfizer, Inc.
  • Bernard Bihain, CEO, Genclis SAS
  • Bernard Huber, Chief Executive Officer and Founder, Oryx Translational Medicine
  • Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
  • Bernhard Sixt, CEO, ImmunID
  • Beth Jacobs, Managing Partner, Excellentia Global Partners
  • Bill Blair, Head of Business Creation, Edinburgh BioQuarter
  • Bill Mullen, CEO, Momentum Bioscience Ltd.
  • Bob Pooler, Sr. Healthcare Analyst, valuationLAB AG
  • Carina Schmidt, CEO, Athera Biotechnologies AB
  • Carlos Buesa, CEO, Oryzon Genomics
  • Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
  • Celia Zinger, Director Medical Affairs, Immune Pharmaceuticals, Inc.
  • Chandra Leo, Partner, HBM Partners AG
  • Charlie Alexander, Lead - BD Transactions, Shire Pharmaceutical
  • Chris Britten, Managing Director, Torreya Partners (Europe) LLP
  • Chris Maggos, Managing Director, Europe, LifeSci Advisors
  • Chris Marai, Executive Director, Oppenheimer & Co.
  • Chris Moriarty, Global Manager, Pharma Sciences Division, Randox Laboratories Ltd.
  • Christian Glennie, Head of Research, Healthcare, Edison Investment Research
  • Christian Lach, Portfolio Manager, Analyst, Bellevue Asset Management AG
  • Christoph Pittius, VP, Head of Transactions, BD, AstraZeneca AB
  • Clive Stanway, CSO, Cancer Research Technology Ltd.
  • Crist Frangakis, CEO and President, Achelios Therapeutics, Inc.
  • Daniel Anizon, Financial Analyst, Independent Consultant
  • David Colpman, Director, Colpman Consulting Ltd.
  • David Horn Solomon, President & CEO, Bionor Pharma A/S
  • David Phillips, Partner, S.R. One Ltd.
  • David Stueber, Managing Director Depositary Receipts, Head of Western Europe, BNY Mellon
  • Deborah Harland, Partner, S.R. One Ltd.
  • Deborah Van Riet, Director, Future Therapeutics & Technologies, Integrated Science & Technology, AbbVie
  • Detlev Mennerich, Investment Manager, Boehringer Ingelheim Venture Fund GmbH
  • Donnie McGrath, Vice President, Search and Evaluation, Business Development, Bristol-Myers Squibb
  • Prof. Dorothee Holm-von Laer, Co-founder and CEO, ViraTherapeutics GmbH
  • Eckhard Leifke, VP External Opportunities CV & Metabolism, Sanofi
  • Eduardo Margallo, CEO, MedLumics S.L.
  • Edwin Constable, Head of Research,  Professor of Chemistry at the University of Basel and Project leader and Member of the Management Board within the SNI
  • Erik Buntinx, Founding CEO, PNBDevCo
  • Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG
  • Eugene Seymour, CEO, NanoViricides, Inc.
  • Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research
  • Fintan Walton, CEO and Founder, PharmaVentures
  • Florian Schödel, Owner, Phillimmune, LLC
  • François Thomas, Managing Director, Thomas Conseil SPRL
  • Frank Grams, VP, Head of R&D Alliance Management & Contracting, Sanofi
  • Frederic Desdouits, Head of Corporate BD & Acquisitions, Pierre Fabre
  • Gaudenz von Capeller, CFO, PIQUR Therapeutics AG
  • Geert Cauwenbergh, President and CEO, RXi Pharmaceuticals Corporation
  • Genghis Lloyd-Harris, Partner, Abingworth LLP
  • Hakan Goker, Senior Investments Director, MS Ventures
  • Harold Van Wart, President and Chief Executive Officer, Director, CymaBay Therapeutics
  • Hendrik Liebers, CFO, Probiodrug AG
  • Iain Dukes, SVP Business Development & Licensing, Merck Research Laboratories
  • James Sapirstein, CEO, ContraVir Pharmaceuticals, Inc.
  • Jana Watson-Capps, Associate Director and Head of Strategy, University of Colorado BioFrontiers Institute
  • Jane Atkins, Director S&E, Center for External Innovation, Takeda Pharmaceuticals International GmbH
  • Jeff Baxter, Chief Executive Officer, VBI Vaccines
  • Jim Phillips, CEO, Midatech Pharma PLC
  • Jim Steel, Head of Healthcare and Life Sciences, Corporate Finance, Peel Hunt LLP
  • João Miguel Santos Pereira, CEO, Magnomics
  • Joël Crouzet, CEO & CSO, InnaVirVax
  • Johannes Zanzinger, Global Head, BD & Licensing Cardiometabolic Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Joshua Resnick, Head of Merck Research Laboratories Ventures, Merck
  • Jutta Roth, Business Development Manager, University of Oxford
  • Katherine Cohen, CEO, Hookipa Biotech AG
  • Katya Smirnyagina, Partner, Capricorn Venture Partners
  • Kia Motesharei, Head, Immunology Licensing, EMD Serono
  • Klaus D. Mendla, Global Head, BD & Licensing CNS, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Lars Gredsted, Senior Business Analyst, Wellcome Trust
  • Laura Lane, Business Development Manager, Warwick Ventures Ltd.
  • Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
  • Laurenz Kellenberger, Chief Scientific Officer, Basilea
  • Lisa M. Rhoads, Managing Director, Easton Capital
  • Loic Vincent, Head, Oncology External Innovation, Sanofi
  • Lorenza Castellon, Business Development Consultant, Suda Ltd.
  • Lubor Gaal, Head of Licensing and External Innovation, Almirall, S.A.
  • Maarit Merla, Head of Business Development, Forendo Pharma Ltd.
  • Malcolm Weir, Co-Founder and CEO, Heptares Therapeutics
  • Marc Martinell, CEO, Mynoryx Therapeutics S.L.
  • Maria Flocco, Senior Director, Head Strategic Research Partnerships Europe, Pfizer
  • Maria Hassard, Deputy Director of Research & Development, Moorfields Biomedical Research Centre
  • Margarita Chavez, Director, Ventures Investments, AbbVie, Inc.
  • Mark J. Pykett, CEO, Agilis Biotherapeutics
  • Markus Goebel, Partner, Novartis Venture Fund
  • Markus Hosang, General Partner, BioMedPartners AG
  • Martin McGlynn, President & Chief Executive Officer, StemCells, Inc.
  • Masa Yuhara, General Manager, Business Development, Mitsubishi Tanabe Pharma Europe Ltd.
  • Matthew Durdy, CBO, Cell Therapy Catapult
  • Melya Hughes Crameri, Head of Business Development, Europe, Amunix Operating, Inc.  
  • Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG
  • Miro Venturi, Global Head, Diagnostics Biomarkers, F.Hoffmann-La Roche Ltd
  • Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S
  • Nathalie ter Wengel, Director of Business Development, Galapagos
  • Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners
  • Nicholas Benedict, Co-Founder & CEO, Allecra Therapeutics
  • Nicholas Franco, EVP  & Chief Business Development Officer, Actelion Pharmaceuticals Ltd.
  • Nicola Thompson, Head, Office of External Drug Discovery, F. Hoffmann La Roche AG
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Oliver Middendorp, Co-CEO and CBO, Numab AG
  • Oliver Siegal, CEO, AFFiRiS AG
  • Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel
  • Patrick Doyle, President, KineMed, Inc.
  • Paul Lammers, President and CEO, Mirna Therapeutics, Inc.
  • Paul Rennert, Founder & Principal, SugarCone Biotech LLC
  • Pascale Augé, CEO, Inserm Transfert
  • Pedro Lichtinger, CEO, Asterias Biotherapeutics
  • Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc.
  • Peter Homberg, Partner/Lawyer, Dentons Europe LLC
  • Peter Nolan, CBO, Oxford Biomedica Ltd.
  • Peter Sandor, Vice President, Global Marketing Oncology TA, Amgen, Inc.
  • Peter Zerhouni, Chief Executive Officer, InDex Pharmaceuticals AB
  • Philippe Calais, CEO, Isarna Therapeutics GmbH
  • Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, EMD Serono, Inc.
  • Punit Dhillon, Co-Founder, President & CEO, OncoSec Medical, Inc.
  • Rahul Ballal, Director, Business Development, Flexion Therapeutics
  • Rainer Metzger, VP, Global Business Development Pharma, QIAGEN GmbH
  • Rainer Strohmenger, General Partner, Wellington Partners
  • Rao Movva, Distinguished Scientist, Novartis Institutes for BioMedical Research
  • Ronald Kempers, President & CEO, Mymetics Corporation
  • Rudi Pauwels, CEO, Biocartis NV
  • Saad Gilani, Managing Director & Head of Healthcare Investments, Yorkville Advisors LLC
  • Seth Lederman, CEO, Tonix Pharmaceuticals Holding Corp.
  • Shane Maloney, Business Development Director, AstraZeneca
  • Simon Blake, Sr. Director Scientific Licensing, Janssen Pharmaceuticals
  • Søren Møller, Managing Investment Director, Novo Seeds, Novo A/S
  • Sten Verland, Partner, Sunstone Capital A/S
  • Stéphane Boissel, Chief Executive Officer, TxCell
  • Stephanie Leouzon, Principal and Head of Torreya Partners Europe, Torreya Partners (Europe) LLC
  • Stephen Brozak, Managing Partner and President, WBB Securities, LLC
  • Stephen Helliwell, Senior Investigator, Novartis Institutes for Biomedical Research
  • Stephen Sands, Commercial Lead Oncology/Immunology, F.Hoffmann-La Roche AG
  • Thomas Hanke, EVP Immunology & Inflammation, Evotec International GmbH
  • Thomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
  • Thomas Meier, Chief Executive Officer, Santhera 
  • Thomas Stockman, Director, European Healthcare Investment Banking, Royal Bank of Canada
  • Tim Dyer, CEO, Addex Therapeutics
  • Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZaneca
  • Tim Luker, Senior Director, External Innovation, Eli Lilly & Company
  • Timothy Morris, CFO, Head of BD, AcelRx Pharmaceuticals, Inc.
  • Ursula Ney, CEO, Genkyotex S.A.
  • Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.
  • Vivek Ramaswamy, CEO, Axovant Sciences
  • Wim Jongen, CEO, Glycostem Therapeutics Corporation
  • And more to be announced...
Financial/Advisory/
Investors Attending:
AbbVie Biotech Ventures
Abingworth LLP
ACXIT Lifesciences GmbH
Advent Life Sciences
Aescap Venture
Aravis SA
Arcus Ventures
BB Biotech Ventures
Bellevue Asset Management
Belsize Asset Management
Bergmann zur Hausen & Cie.
BioGeneration Ventures
BioMedPartners AG
Breslin AG
BZ Bank Aktiengesellschaft
Capricorn Venture Partners
Catalysis Capital Partners
CBT Advisors
CD-Venture GmbH
Cederberg GmbH
Cukierman & Co. Life Sciences
Deloitte LLP
Deutsche Bank AG
Edison Group
Edmond de Rothschild Investment Partners
Eminent Venture Capital Corporation / TaiAn Technologies
Ernst & Young
Excellentia Global Partners
Forbion Capital Partners
FreeMind Group
Gilde Healthcare
Global Life Science Ventures
HBM Partners AG
Hestia Investments
High-Tech Gruenderfonds Management GmbH
Ikarian Capital
Imperial College Innovations
Inbio Ventures
Industrifonden
Inserm Transfert
Inserm Transfert Initiative
IPF Partners
IPSA
JPI Funds
JSB Partners LP
KarinJorga Life Science Consulting GmbH
LSP
Lundbeckfond Ventures
MedImmune Ventures, Inc.
Mediqventures
MedTech Innovation Partners AG
MedVenture Partners GmbH
Ventures
Mercadyne Investments, LLC
Mirabaud Securities LLP
MPM Capital
MS Ventures
MSD Research Laboratories Muse Capital LLP
NetScientific UK
Nextech Invest Ltd.
Norgine Ventures
Novartis Venture Fund
Novo A/S
NRW Bank
Omega Funds
Oxford Finance, LLC
PARfinance
Peel Hunt LLP
Percipient Capital
PharmaVentures Ltd.
Remaco AG
RMI Partners
Rockport Venture Partners
Royal Bank of Canada (Suisse)
S.R.One, Limited
Salus Partners
Seroba Kernel Life Sciences
Seventure Partners
Silicon Valley Bank
Sirius Healthcare Partners
SIX Swiss Exchange
Sixth Element Capital
Societe Generale
Stifel Financial Corp.
Sunstone Capital A/S
Syncona Partners
Thuja Capital B.V.
Torreya Partners (Europe) LLC
TVM Capital
UBS AG
Ventac Partners GmbH
VI Partners AG
Visium Asset UK LLP
Vogel BioC
Vontobel Bank
Warwick Ventures
WBB Capital
WBB Securities, LLC
Wellington Partners
XOventure GmbH
Yorkville Advisors, LLC
Ysios Capital Partners
ZukunftsAgentur Brandenburg GmbH
Zukunftsfonds Heilbronn GmbH & Co KG
Zürcher Kantonalbank